NL-OMON21732已完成不适用
Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoprotein oxidized low density lipoprotein
.A.0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
.A.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- •1.Male, aged 18-45 without evidence of any active or chronic disease following a medical history, a complete physical examination including vital signs, 12-lead ECG, haematology, blood chemistry and urinalysis.
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •1.Subjects vaccinated with a pneumococcus vaccine
研究者
相似试验
进行中（未招募）
1 期
Pneumococcal vaccine against atherosclerosisHealthy male volunteersMedDRA version: 19.0Level: LLTClassification code 10003601Term: AtherosclerosisSystem Organ Class: 100000004866EUCTR2015-005650-35-NLCentre for Human Drug Research24
已完成
2 期
Proof-of-pharmacology clinical trial on a vaccine that elicits a protective humoral immune response against oxidized low density lipoproteiHypercholesterolemie10003216AtherosclerosisNL-OMON43410Centre for Human Drug Research24
已完成
1 期
Phase I/IIa Dose-escalation Clinical Study of VAC-3SHIV-1 InfectionNCT01549119InnaVirVax33
Unknown
1 期
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)Cancer.Melanoma.Ovarian Cancer.Lung Cancer.NCT01584115Instituto de Investigação em Imunologia15
Unknown
2 期
EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19SARS-CoV-2NCT05059106Federal University of Espirito Santo29,637